Scientists used genetic data to look at whether GLP-1 receptor agonists affect dementia risk. These drugs are commonly used for Type 2 Diabetes and Obesity. The analysis looked at people in the UK Biobank, FinnGen, and All of Us databases. The goal was to see if lowering blood sugar with these medicines could protect the brain.
The results showed a clear difference between dementia types. People with genetic markers for GLP-1 use had a 17% lower risk of vascular dementia. This is the kind of dementia linked to blood vessel health. However, the data did not show a consistent link for Alzheimer's disease or all-cause dementia overall. In one large group, the risk for Alzheimer's appeared higher, but the combined results showed no clear effect.
Researchers also found that genetic signals for these drugs were linked to greater total brain volume. This suggests the drugs might help keep the brain larger. But scientists must wait for results from ongoing clinical trials. These real-world trials will tell us if these drugs actually prevent dementia in living patients. Distinguishing between dementia subtypes is important when evaluating these therapies.